CIBRA Capital’s Esperion Therapeutics ESPR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-164,614
Closed -$520K – 34
2026
Q2
$520K Buy
+164,614
New +$460K 0.23% 27

Other funds holding ESPR

CIBRA Capital's ESPR Position: Q3 2026 in Review

CIBRA Capital sold out of Esperion Therapeutics (ESPR) in Q3 2026, closing a stake of 164,614 shares — an estimated $520K sold.

CIBRA Capital first reported a position in ESPR in Q2 2026 and held it in 1 quarter. The position peaked at $520K in Q2 2026. 2 funds tracked by Wall St. Rank hold ESPR as of Q3 2026.

  • CIBRA Capital reported no remaining Esperion Therapeutics position as of Q3 2026 after selling out during the quarter.
  • CIBRA Capital sold 164,614 Esperion Therapeutics shares in Q3 2026, an estimated $520K.
  • CIBRA Capital first reported a position in Esperion Therapeutics in Q2 2026 and held it in 1 quarter.
  • CIBRA Capital's Esperion Therapeutics position peaked at $520K in Q2 2026.
  • 2 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2026.

Based on CIBRA Capital's 13F filing for Q3 2026, filed 19 Nov 2026.